Establishment of matrix metalloproteinase 3 time-resolved immunoassay and some potential clinical applications.
Anal Biochem
; 666: 115072, 2023 04 01.
Article
en En
| MEDLINE
| ID: mdl-36738873
ABSTRACT
AIM:
To develop a highly sensitive time-resolved fluorescence immunoassay (TRFIA) for the detection of serum matrix metalloproteinase-3 (MMP-3) and to assess MMP-3's clinical value in patients with colorectal cancer (CRC).st.METHODS:
MMP-3 levels were established using the double antibody sandwich technique. The MMP-3 TRFIA technique was developed and optimized, and its linearity, sensitivity, accuracy, specificity, and recovery were assessed. Then, serum concentrations in healthy individuals and patients with CRC were determined by MMP-3 TRFIA.RESULTS:
The linear range of MMP-3 TRFIA was 0.73-500 ng/mL. MMP-3 TRFIA had an intra-batch precision range of 2.16%-7.10% percent and an inter-batch precision range of 3.99%-11.21%. MMP-3, tumor-associated trypsinogen 2, and AFP had no cross reaction.The recovery is between 90% and 110%, and had no serum interference. Patients with CRC had serum MMP-3 levels (73.95 ± 78.43 ng/mL) that were considerably higher than those of healthy individuals (21.45 ± 11.12 ng/mL), and those with metastasis had serum MMP-3 levels (95.89 ± 76.21 ng/mL) that were considerably higher than those of patients without metastasis (52.74 ± 47.25 ng/mL).CONCLUSIONS:
A highly sensitive MMP-3 TRFIA assay was successfully developed, and serum MMP-3 may be associated with CRC invasion and metastasis. Therefore, MMP-3 can be used in the auxiliary diagnosis of CRC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Fluoroinmunoensayo
/
Metaloproteinasa 3 de la Matriz
Límite:
Humans
Idioma:
En
Revista:
Anal Biochem
Año:
2023
Tipo del documento:
Article
País de afiliación:
China